Following a limited submission
AWMSG advice |
||||
| Status: Recommended | ||||
Opicapone (Ongentys®) is recommended as an option for use within NHS Wales as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations. |
||||
|
||||
Medicine details |
||||
| Medicine name | opicapone (Ongentys®) | |||
| Formulation | 50 mg hard capsule | |||
| Reference number | 5285 | |||
| Indication | Adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations |
|||
| Company | Bial – Portela & Cª, S.A | |||
| BNF chapter | Central nervous system | |||
| Submission type | Limited | |||
| Status | Recommended | |||
| Advice number | 0324 | |||
| NMG meeting date | 10/04/2024 | |||
| AWMSG meeting date | 14/05/2024 | |||
| Date of issue | 15/05/2024 | |||
| Further information This advice incorporates and replaces the existing AWMSG recommendation for opicapone (Ongentys®) as an adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations, restricted within the licensed indication for use after failure of entacapone, or in patients who cannot tolerate entacapone (AWTTC reference number 911, originally published March 2021). |
||||